Literature DB >> 31730152

Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations.

Krista F Huybrechts1, Sonia Hernandez-Diaz2, Loreen Straub1, Kathryn J Gray3, Yanmin Zhu1, Helen Mogun1, Brian T Bateman1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31730152      PMCID： PMC6865841          DOI： 10.1001/jama.2019.18587

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  5 in total

1.  Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in Offspring.

Authors:  Krista F Huybrechts; Sonia Hernández-Díaz; Loreen Straub; Kathryn J Gray; Yanmin Zhu; Elisabetta Patorno; Rishi J Desai; Helen Mogun; Brian T Bateman
Journal:  JAMA       Date:  2018-12-18       Impact factor: 56.272

2.  A Propensity-score-based Fine Stratification Approach for Confounding Adjustment When Exposure Is Infrequent.

Authors:  Rishi J Desai; Kenneth J Rothman; Brian T Bateman; Sonia Hernandez-Diaz; Krista F Huybrechts
Journal:  Epidemiology       Date:  2017-03       Impact factor: 4.822

Review 3.  Use of real-world evidence from healthcare utilization data to evaluate drug safety during pregnancy.

Authors:  Krista F Huybrechts; Brian T Bateman; Sonia Hernández-Díaz
Journal:  Pharmacoepidemiol Drug Saf       Date:  2019-05-10       Impact factor: 2.890

4.  First trimester ondansetron exposure and risk of structural birth defects.

Authors:  April Zambelli-Weiner; Christina Via; Matt Yuen; Daniel J Weiner; Russell S Kirby
Journal:  Reprod Toxicol       Date:  2018-10-29       Impact factor: 3.143

5.  Harnessing the Medicaid Analytic eXtract (MAX) to Evaluate Medications in Pregnancy: Design Considerations.

Authors:  Kristin Palmsten; Krista F Huybrechts; Helen Mogun; Mary K Kowal; Paige L Williams; Karin B Michels; Soko Setoguchi; Sonia Hernández-Díaz
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240
  5 in total
  3 in total

1.  Risk of abnormal pregnancy outcomes after using ondansetron during pregnancy: A systematic review and meta-analysis.

Authors:  Xiao Cao; Mingyao Sun; QiuYu Yang; Qi Wang; Liangying Hou; Jing Wang; Yu Wu; Long Ge
Journal:  Front Pharmacol       Date:  2022-09-02       Impact factor: 5.988

2.  The Canadian Mother-Child Cohort Active Surveillance Initiative (CAMCCO): Comparisons between Quebec, Manitoba, Saskatchewan, and Alberta.

Authors:  Anick Bérard; Padma Kaul; Sherif Eltonsy; Brandace Winquist; Dan Chateau; Steven Hawken; Ann Sprague; Mark Walker; Sasha Bernatsky; Michal Abrahamowicz; Cristiano Soares de Moura; Évelyne Vinet; Bruce Carleton; Gillian Hanley; Tim Oberlander; Odile Sheehy; Yessica Haydee Gomez; Jessica Gorgui; Anamaria Savu
Journal:  PLoS One       Date:  2022-09-20       Impact factor: 3.752

3.  Validating the effect of Ondansetron and Mirtazapine In Treating hyperemesis gravidarum (VOMIT): protocol for a randomised placebo-controlled trial.

Authors:  Anne Ostenfeld; Tonny Studsgaard Petersen; Tina Bergmann Futtrup; Jon Trærup Andersen; Andreas Kryger Jensen; Hanne Brix Westergaard; Lars Henning Pedersen; Ellen Christine Leth Løkkegaard
Journal:  BMJ Open       Date:  2020-03-24       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.